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Abstract 
Review on Disseminated Juvenile 
Xanthogranuloma, with data on clinics, and the 
genes involved. 
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Identity 
Other names 
JXG, Benign cephalic histiocytosis, Progressive 
nodular histiocytosis, Generalized (non-lipidemic) 
eruptive histiocytosis (skin), Xanthoma 
disseminatum (skin plus mucosa lesions), Erheim-
Chester disease (adult form with bone and lung 
involvement). 
Clinics and pathology 
Disease 
Phenotype/cell stem origin 
Rudolf Virchow may have been the first to describe 
a child with "cutaneous xanthomas" in 1871 as noted 
in a 1954 report of this condition (Helwig and 
Hackney, 1954). JXG is a histiocytic condition 
(proliferation) in the spectrum of non-Langerhans 
histiocytosis that primarily affects children. The 
disease can be related with germline in 
neurofibromatosis type 1 (NF1) that implicate the 
potential role for MAPK hyperactivity in 
pathogenesis. Histiocytes are cells with specific 
histological and immunogenic properties, 
contributing to the immune response through antigen 
presentation and phagocytosis. JXG is defined by 
pathological infiltration by histiocytes within 
effected tissues. 
Epidemiology 
Preferentially affects children, usually occurs by 10 
years of age, with one-half of reported cases 
occurring in the first year of life.  
Twenty percent of the cases occur in adolescents and 
young adults. Male children are slightly more often 
affected than female children, with reported ratios 
ranging from1.1 to 1.4. 
Clinics 
Skin and soft-tissue presentation are the most 
common sites of involvement and can include the 
mucosal surface of the upper airway.  
Cutaneous presentation consists of benign, usually 
asymptomatic, self-healing, red, yellow or brown 
maculopapular lesions primarily involving the head, 
neck, and trunk.  
These lesions are usually believed to be benign and 
will regress spontaneously leaving a flat, atrophic 
scar or an area of altered pigmentation. Although 
systemic JXG without organ damage can have a 
benign course, CNS disease may be difficult to treat 
and is associated with severe morbidity (can cause 
diabetes insipidus, seizures, hydrocephalus and 
changes in the mental status) and mortality.  
If cytopenias are noted in these patients then bone 
marrow involvement should be ruled out with a bone 
marrow biopsy and aspirate.  
Liver infiltration may be noted in patients with 
elevated liver function testing, hypoalbuminemia, 
and an elevated erythrocyte sedimentation rate. 
Hypercalcemia can also be seen in patients with 
JXG.  
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Differential diagnosis Langerhan's cell histocytosis 
is the disease most often confused with JXG. Others 
disorders in the differential include fibrohistocytic 
lesion NOS, reticulohistiocytoma, 
hemangioendothelioma, Spitz nevus, malignant 
fibrous histiocytoma, and rhabdomyosarcoma or 
other solid tumor malignancies. 
Pathology 
JXG cells are small and oval with a bland, round to 
oval nucleus and pink cytoplasm. Touton cells are 
seen at dermal sites.  
Immunohistochemistry reveals cells that express 
vimentin, lysozyme, CD14, CD68, CD163, stabilin 
1 and factor XIIIa. CD1 is negative. 
Treatment 
Treatments include using treatments similar to 
Langerhans cell histiocytosis including agents such 
as vinblastine, prednisone, and methotrexate. 
Clinical trials and tertiary care center referrals are 
recommended for treatment and evaluation of JXG. 
Prognosis 
Patients with only skin or soft tissue involvement 
have a high survival rate, and lesions can 
spontaneously disappear over time in a majority of 
cases. Infants with large retroperitoneal masses, 
liver, bone marrow, or central nervous system 
involvement usually have good outcomes with  
chemotherapy. Outcomes in older children remain 
unclear due to the lack of published data on patients 
with JXG. 
Genetics 
High prevalence of BRAF V600E, LCH and other 
activating MAPK mutations 
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